Congress should invest in AI and data science training to prepare the next generation of scientists for AI-supported drug development by integrating AI into biomedical research, supporting cross-disciplinary collaboration, and establishing best practices.

To Do: Invest in AI and Data Science Training for Drug Development

Congress should pass the Privacy Enhancing Technology Research Act mandating NSF to support research into privacy-enhancing technologies and directing OSTP to coordinate efforts with other federal agencies to accelerate the technologies’ development, deployment, and adoption.

To Do: Pass the Privacy Enhancing Technology Research Act

Congress should fund NIH’s “All of Us” research program to improve the representativeness of datasets used in biomedical research.

To Do: Improve the Datasets Needed for Biomedical Research

AI can reduce the time it takes to synthesize and screen new drugs by 40 percent to 50 percent, reducing costs in those parts of the research process by as much as $26 billion annually.

Fact of the Week: Artificial Intelligence Can Save Pharmaceutical Companies Almost $54 Billion in R&D Costs Each Year

Congress should fund and direct the National Science Foundation (NSF) to create a competitive AI fellowship program for at least 1,000 computer science students annually.

To Do: Expand Investments in AI Talent

The White House should direct federal agencies to develop sector-specific AI strategies to spur AI adoption and development in industry.

To Do: Develop Sector-Specific AI Strategies

The administration should develop a national AI roadmap that outlines sector-specific opportunities and barriers, as well as a detailed strategy for achieving widespread adoption in each of these sectors.

To Do: Create a National Roadmap for AI Adoption

Congress should fund a pilot program supporting experimental approaches to technology transfer and commercialization, and the administration should require labs to collect metrics, identify barriers, and hold labs accountable. 

To Do: Support Experimental Approaches to Tech Transfer and Commercialization

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.

To Do: Accelerate AI Adoption in Biopharma Research

Recommendation

Details

Editors’ Recommendations

Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry

Related

To Do: Invest in AI and Data Science Training for Drug Development

To Do: Pass the Privacy Enhancing Technology Research Act

To Do: Improve the Datasets Needed for Biomedical Research